Percheron Therapeutics Ltd
ASX:PER
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
PER's latest stock split occurred on Apr 10, 2018
The company executed a 50-for-49 stock split, meaning that for every 49 shares held, investors received 50 new shares.
Before the split, PER traded at 0.0255 per share. Afterward, the share price was about 0.032.
The adjusted shares began trading on Apr 10, 2018. This was PER's 3rd stock split, following the previous one in Nov 6, 2013.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 22, 2026
|
|
Chimeric Therapeutics Ltd
ASX:CHM
|
1-for-100
/100
|
0.002 0.2 AUD | 0.17 0.17 AUD |
|
Apr 22, 2026
|
|
Architects Studio Japan Inc
TSE:6085
|
10-for-1
x10
|
3800 380 JPY | 430 430 JPY |
|
Apr 22, 2026
|
|
Freewon China Co Ltd
SSE:688678
|
1-for-1
x1
|
30.5 21.6857 CNY | 23.64 23.64 CNY |
|
Apr 22, 2026
|
S
|
Sharetronic Data Technology Co Ltd
SZSE:300857
|
1-for-1
x1
|
304.5701 217.2101 CNY | 260.76 260.76 CNY |
|
Apr 21, 2026
|
|
Canon Electronics Inc
OTC:CAOEF
|
1-for-6235122
/6235122
|
16.96 16.96 USD | N/A |
CHM
6085
688678
CAOEF
Percheron Therapeutics Ltd
Glance View
Percheron Therapeutics Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The firm is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.
